Psilocybin and Chronic Pain: What Does the Science Really Say?

By Joseph Santiago – Founder of Microdose Bros

Chronic pain is one of the most persistent and under-solved problems in modern medicine. An estimated 20 to 30 percent of adults in Europe live with some form of chronic pain, and for many of them, conventional treatments offer limited, inconsistent, or side-effect-heavy relief. Anti-inflammatories, opioids, anticonvulsants, antidepressants — the toolbox is wide but imperfect. For a growing number of people, the relief simply never comes.

Against this backdrop, a quiet scientific conversation has been building for several years. Researchers, clinicians, and patients are asking whether psilocybin — the active compound in so-called “magic mushrooms” — might offer something the existing pharmacopeia cannot. The question is serious. So are the caveats.

This article explores what the science currently shows about psilocybin and chronic pain, where the evidence is genuinely promising, where it falls short, and what we still do not know.

What Is Psilocybin?

Psilocybin is a naturally occurring psychedelic compound found in over 200 species of fungi, most famously in the Psilocybe genus. When ingested, the body converts it into psilocin, which acts primarily on serotonin receptors in the brain — particularly the 5-HT2A receptor. This interaction triggers a cascade of neurological effects, including altered perception, intensified emotion, and a measurable disruption of the brain’s default mode network — the system thought to underlie our habitual sense of self.

Psilocybin is a controlled substance across most of Europe. In the Netherlands, psilocybin mushrooms have been prohibited since 2008, though magic truffles — the underground sclerotia of the same fungi — occupy a unique legal position and are sold openly in licensed smartshops. When the Dutch government banned magic mushrooms under the Opium Act, the legislation specifically targeted above-ground fruiting bodies; truffles, which grow underground, were not included. Whether this was a deliberate policy choice or a legislative oversight remains genuinely unclear. The result is that magic truffles and grow kits are legally available in the Netherlands, while pure isolated psilocybin and dried mushrooms are not.

It is also worth noting that psilocybin is not an approved medicine anywhere in the EU at the time of writing. Scientific research conducted under institutional oversight is legally permitted, and a number of such programmes are active across Europe and beyond.

Its therapeutic potential has attracted growing institutional interest. Well-funded clinical programs at institutions including Imperial College London, Johns Hopkins University, and NYU have produced peer-reviewed data across several mental health conditions. Pain research is now following in that wake.

How Chronic Pain Works in the Brain

To understand why researchers are studying psilocybin for pain, it helps to understand what chronic pain actually is — and what it is not.

Acute pain is biological alarm. It warns you that tissue is damaged and prompts protective behaviour. Chronic pain, defined as pain persisting for more than three months, is a fundamentally different phenomenon. It is not simply acute pain that has overstayed its welcome. In many cases, the original injury has healed, but the nervous system continues to generate and amplify pain signals.

This process — called central sensitization — involves structural and functional changes in the brain and spinal cord. The brain essentially learns to be in pain. Neural pathways become reinforced. The default mode network, the thalamus, and the anterior cingulate cortex all play roles in how pain is experienced, anticipated, and remembered. Emotional states, past trauma, and psychological factors are not merely “in the head” — they are embedded in the same neural architecture that processes pain.

This is precisely why researchers are paying attention to psilocybin. A compound that demonstrably reorganises patterns of neural connectivity, quiets overactive brain networks, and disrupts rigid, habitual thought processes is — at least theoretically — worth investigating in the context of a condition that involves exactly those pathways.

What the Current Research Shows

It is important to be direct here: the clinical evidence for psilocybin as a treatment for chronic pain is preliminary. There are no large-scale randomised controlled trials. There are no approved therapeutic protocols. What exists is a collection of early-phase trials, observational studies, case reports, and preclinical work in animal models — all intriguing, but none sufficient to draw firm conclusions.

A 2023 systematic review published in Frontiers in Pain Research examined the existing literature on psychedelic-assisted interventions for pain. The authors identified a small but growing body of evidence suggesting that classic psychedelics, including psilocybin, may reduce pain intensity and improve pain-related psychological outcomes. They also noted that most studies are limited by small sample sizes, lack of blinding, heterogeneous populations, and inconsistent outcome measures. The reviewers called for rigorous Phase II and Phase III trials before anyone could make clinical recommendations.

A 2022 study from the University of Alabama at Birmingham examined psilocybin’s effects on phantom limb pain — one of the most treatment-resistant forms of neuropathic pain. In a small open-label trial, several participants reported meaningful reductions in pain following psilocybin sessions. The effect sizes were notable, though the absence of a placebo control makes causation difficult to establish.

Research out of Imperial College London has explored how psychedelic experiences can shift the relationship between a person and their pain — not simply reducing the signal, but altering how they interpret and integrate it. This aligns with existing frameworks in pain psychology, which emphasise that the subjective experience of pain is as clinically significant as its neurobiological substrate.

None of this is conclusive. These are early findings in small populations, often conducted without placebo controls, and published in journals of varying impact. What they offer is scientific plausibility and a foundation for further inquiry.

Types of Pain That May Be Affected

While the research is broad and uneven, certain pain conditions have attracted more focused attention.

Cluster Headaches and Migraines

This is arguably where the anecdotal and preliminary clinical evidence is most compelling. Cluster headaches — sometimes called “suicide headaches” because of their intensity — are notoriously difficult to treat. A series of surveys and observational studies, including work published in Cephalalgia and Neurology, found that a significant proportion of cluster headache patients report that sub-perceptual doses of psilocybin appear to reduce attack frequency and intensity. Some report sustained remission after a single or small number of doses.

Researchers hypothesise that psilocybin’s action on serotonin receptors and its potential effects on inflammatory signalling pathways may be relevant — though the mechanisms are not fully understood. Yale University is among the academic centres pursuing formal clinical research in this area.

For migraines, a double-blind, placebo-controlled pilot study published in Neurotherapeutics in 2021 found that a single low dose of psilocybin produced a significant reduction in migraine frequency in the two weeks after administration. The sample size was small — twelve participants — but the design was rigorous by early-phase standards.

Neuropathic Pain

Neuropathic pain, caused by damage or dysfunction in the nervous system itself, affects millions of people and is one of the hardest conditions to treat pharmacologically. Preclinical evidence suggests psilocybin may have anti-nociceptive properties — meaning it can reduce the transmission of pain signals — through serotonin receptor modulation and neuroplasticity. Human trial data remains sparse, but researchers consider the theoretical basis credible enough to warrant further investigation.

Fibromyalgia and Central Sensitization Syndromes

Fibromyalgia, irritable bowel syndrome, and related conditions involve widespread pain amplification without clear peripheral tissue damage. Given psilocybin’s documented effects on the default mode network and its role in shifting entrenched cognitive patterns, some researchers consider these conditions particularly worth studying. Early qualitative research has reported that some fibromyalgia patients describe meaningful improvements in their relationship to pain following psychedelic experiences, though controlled data is not yet available.

Why Results Vary: Set, Setting, and Dosage

Anyone familiar with psychedelic research quickly encounters the concept of “set and setting” — the idea that a person’s internal state (mindset) and external environment profoundly shape the experience and its outcomes. This is not a soft, anecdotal concept. Empirical data increasingly supports it.

The dose matters enormously. A microdose — typically a sub-perceptual amount that produces no overt psychedelic effect — sits at the opposite end of the spectrum from a full therapeutic dose used in clinical research settings (typically 20 to 30 mg of pure psilocybin). Most clinical pain research has focused on moderate to high doses in structured therapeutic settings. The two contexts are not interchangeable, and conclusions from high-dose trials should not apply directly to microdosing practises without dedicated research.

Psychological preparation, the presence of trained guides or therapists, post-session integration support, and the physical environment all appear to influence outcomes. Results from clinical trials — conducted in carefully controlled, professionally supported settings — may not translate directly to unstructured self-administration.

Individual variation also plays a significant role. Genetics, prior trauma, existing mental health conditions, and pain chronicity all affect how a person responds. There is no universal outcome.

Risks and Safety Considerations

Psilocybin has a well-established safety profile relative to many controlled substances. It is not considered physiologically addictive, and researchers have not documented a lethal overdose in humans in the scientific literature. However, this does not mean it is without risk.

Psychological and Psychiatric Risks

Acute psychological distress during a session — commonly called a “difficult experience” or, colloquially, a “bad trip” — is a real possibility, particularly at higher doses. For individuals with a personal or family history of psychosis, schizophrenia, or bipolar disorder, psilocybin may trigger or exacerbate symptoms. Researchers treat this as a clinical contraindication.

If you are using truffles and find yourself in an uncomfortable experience, a trip stopper can help ease the intensity. Products like Psyche Stop are designed to reduce the effects of psilocybin when a session becomes overwhelming — a practical harm reduction tool worth knowing about before you begin.

Other Risks to Know

Hallucinogen persisting perception disorder (HPPD) — a condition involving persistent perceptual disturbances after psychedelic use — is rare but documented.

Drug interactions are also a concern. Do not combine psilocybin with lithium (risk of seizures), monoamine oxidase inhibitors, or certain other psychiatric medications without medical guidance.

For anyone managing chronic pain with existing medications, consulting a qualified medical professional before any consideration of psychedelic use is essential. Nothing in this article constitutes medical advice.

The Future of Research

The pace of scientific activity in this space is accelerating. Multiple Phase II trials are underway or in development examining psilocybin for pain-related indications, including work conducted under regulatory frameworks in the UK, US, and parts of continental Europe. The UK has granted several research licences in recent years specifically for psychedelic pain research.

Biotech companies including Compass Pathways and Usona Institute are advancing psychedelic-assisted therapy programmes, some of which touch on pain-adjacent conditions. Academic-industry partnerships are generating better-designed trials with larger cohorts and more rigorous controls.

The Blinding Problem

One methodological challenge researchers continue to grapple with is blinding. Conducting a truly double-blind trial with a substance that produces a distinctly noticeable altered state is difficult. Participants often know whether they received an active dose or a placebo. This complicates the interpretation of results and drives active methodological debate in the field.

What the next decade of research may clarify includes which pain conditions respond best, what dose and frequency are optimal, how long effects persist, and which patient populations are most likely to benefit — or face risk.

A Balanced Conclusion

Psilocybin is not a miracle treatment for chronic pain. It is a pharmacologically interesting compound with a scientifically plausible mechanism of action, some genuinely encouraging early data, and a very long road of rigorous research ahead of it before anyone could responsibly make clinical recommendations.

The suffering of chronic pain patients is real and urgent. That urgency makes it tempting to extrapolate far beyond what the evidence currently supports. Responsible engagement with this science means holding two things at once: genuine intellectual openness to what psilocybin might offer, and disciplined honesty about how much we do not yet know.

For those living with treatment-resistant chronic pain, it is understandable to look toward emerging therapies with hope. The science suggests that hope is not entirely misplaced. But it also suggests patience, caution, and a commitment to following the evidence where it actually leads — rather than where we wish it would.

If you are based in the Netherlands and curious to explore psilocybin in a legal context, magic truffles and grow kits are available through licensed smartshops. Those interested in sub-perceptual use can explore microdosing products as a separate avenue entirely. Whatever your interest, approaching any psychedelic experience with preparation, respect, and access to harm reduction tools — including a trip stopper if needed — is always the wisest starting point.

If you are considering psychedelic therapy for any health condition, speak with a qualified medical professional. Access to legal, supervised psychedelic therapy varies by country and is evolving. In the Netherlands and across the EU, the regulatory landscape is developing, and informed, expert guidance is irreplaceable.

Follow Microdose Bros

Stay connected and be part of the journey. We share insights on microdosing, psychedelic education, new products, and behind-the-scenes moments from our shop in Utrecht.

Follow us on your favorite platform:

Join our community and stay inspired.

This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a basis for clinical decisions. Always consult a qualified healthcare provider before making decisions about your health.